Pancreatic Cell Fate: To be or not to be
Chromatin remodeling processes can drive acinar cell fate decisions.
- University Medical Center Goettingen, Germany
Every single cell in the body contains the same genetic information. However, different types of cells activate distinct sets of genes at different times and locations, which allows them to carry out their precise roles. How do cells achieve this?
The answer lies in a specific structure called chromatin, which is formed of nucleosome units, in which a defined amount of DNA is wrapped around a core of histone proteins. To activate a specific gene, the chromatin first needs to be remodeled to provide access to the transcription machinery (Strahl and Allis, 2000). This process is firmly controlled by chromatin remodeling proteins, which disrupt the tight contact between DNA and histones, and mobilize the nucleosomes to reveal the ‘hidden’ genes (Owen-Hughes, 2003; Bossen et al., 2015).
Failures in the chromatin remodeling machinery can severely hamper the function of a cell, or worse, foster malignant transformations that can lead to cancer (Feinberg et al., 2016; Plass et al., 2013; Wilson and Roberts, 2011). This affects in particular the subunits of the chromatin remodeling complex called SWI/SNF (Kadoch et al., 2013). So far, it has remained unclear how mutations within this structure can lead to the development of tumors. Now, in eLife, Scott Lowe and colleagues from the Memorial Sloan Kettering Cancer Center, the Hannover Medical School and the University of Michigan – including Geulah Livshits as first author – report how a subunit of SWI/SNF, called Arid1a, is involved in the development of pancreatic cancer (Livshits et al., 2018).
Pancreatic cancer is one of the most aggressive types of cancer, with a five-year survival rate of less than 8% (Siegel et al., 2016). Around a quarter of pancreatic cancers contain mutations in the SWI/SNF complex, which are commonly accompanied by mutations in a gene called Kras (Hingorani et al., 2003). Now, Livshits et al. elegantly introduce the subunit Arid1a as a pivotal player in directing the fate of acinar cells – the cells that produce digestive enzymes to help break down food – in the presence of the cancer-causing or oncogenic Kras.
The researchers engineered a mouse model with a Kras mutation that allowed them to turn off Arid1a specifically in the acinar cells by feeding the mice antibiotics. When comparing the pancreas of adult mice with either a Kras mutation only, with deactivated Arid1a only, or with both a Kras mutation and deactivated Arid1a, the results revealed that the consequences of removing Arid1a were determined by the Kras mutation status and the time point of Arid1a depletion in relation to oncogenic activation of Kras (Figure 1).
Figure 1
Schematic illustration of the molecular changes that can alter the identity of acinar cells in the pancreas.
Livshits et al. show that a subunit of the chromatin remodeling protein SWI/SNF, called Arid1a, could contribute to the development of pancreatic cancer. (A) Mice without a Kras mutation and without Arid1a (yellow) did not show any cancer symptoms, suggesting that a lack of Arid1a alone cannot drive the reprogramming of acinar cells (pink). (B) Inactivating Arid1a in the context of a preexisting Kras mutation irreversibly boosts the development of pancreatic cancer (PDAC). (C) Removing Arid1a at the same time as activating the Kras mutation (KrasG12D, red) does not accelerate the formation of precursor lesions that could lead to pancreatic cancer.
Mice without a Kras mutation and without Arid1a did not show any precancerous lesions in their cells, suggesting that the SWI/SNF protein may be dispensable for maintaining the architecture of acinar cells in the absence of oncogenic Kras (Figure 1A). However, inactivating Arid1a in the context of a preexisting Kras mutation significantly accelerated the symptoms of the mice within two weeks: the acinar cells of these mice started to transform into a different phenotype and stopped producing digestive enzymes – instead, they started making other proteins, such as mucins, which are typically found in precancerous or cancerous cells in the pancreas (Figure 1B). Most importantly, these symptoms remained irreversible, even when the antibiotics were removed.
Removing Arid1a in mice embryos at the same time as activating the Kras mutation did not have the same effect (Figure 1C): as the Kras mutation alone eventually leads to formation of pancreatic cancer. The thorough histological and molecular analyses of Livshits et al. demonstrate that a lack of Arid1a can increase the sensitivity of acinar cells to oncogenic signals, leading to the formation of pancreatic cancer. Nevertheless, Arid1a’s contribution to pancreatic carcinogenesis strongly depends on the molecular (mutated Kras) and temporal context (when the Kras mutation occurs).
Due to Arid1a’s ability to influence cell fate, a loss of Arid1a combined with a Kras mutation may therefore severely alter the composition of chromatin. Indeed, when Livshits et al. looked at the chromatin organization, it showed that mice without Arid1a had an abnormal chromatin structure, with genes encoding digestive enzymes being less accessible than in mice with normal Arid1a levels.
Together, the data by Livshits et al. characterize Arid1a as a critical but context-dependent gate keeper of acinar cell fate and pancreatic carcinogenesis. Since chromatin regulatory proteins control reversible processes, they represent promising targets for new therapeutic approaches in cancer treatment. Hence, disentangling the interdependence of the chromatin regulatory protein and context-defining molecular changes in the development of pancreatic cancer and other malignancies, constitutes a difficult but crucial challenge of future studies in the field.
References
-
Epigenetic modulators, modifiers and mediators in cancer aetiology and progressionNature Reviews Genetics 17:284–299.https://doi.org/10.1038/nrg.2016.13
-
Pathways for remodelling chromatinBiochemical Society Transactions 31:893–905.https://doi.org/10.1042/bst0310893
-
Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancerNature Reviews Genetics 14:765–780.https://doi.org/10.1038/nrg3554
-
Cancer statistics, 2016CA: A Cancer Journal for Clinicians 66:7–30.https://doi.org/10.3322/caac.21332
-
SWI/SNF nucleosome remodellers and cancerNature Reviews Cancer 11:481–492.https://doi.org/10.1038/nrc3068
Article and author information
Author details
Elisabeth Hessmann
Publication history
Copyright
© 2018, Zhang et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,154
- views
-
- 119
- downloads
-
- 1
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Pancreatic Cell Fate: To be or not to be
eLife 7:e38967.
https://doi.org/10.7554/eLife.38967
Further reading
-
- Cancer Biology
Tumor neoantigen peptide vaccines hold potential for boosting cancer immunotherapy, yet efficiently co-delivering peptides and adjuvants to antigen-presenting cells in vivo remains challenging. Virus-like particle (VLP), which is a kind of multiprotein structure organized as virus, can deliver therapeutic substances into cells and stimulate immune response. However, the weak targeted delivery of VLP in vivo and its susceptibility to neutralization by antibodies hinder their clinical applications. Here, we first designed a novel protein carrier using the mammalian-derived capsid protein PEG10, which can self-assemble into endogenous VLP (eVLP) with high protein loading and transfection efficiency. Then, an engineered tumor vaccine, named ePAC, was developed by packaging genetically encoded neoantigen into eVLP with further modification of CpG-ODN on its surface to serve as an adjuvant and targeting unit to dendritic cells (DCs). Significantly, ePAC can efficiently target and transport neoantigens to DCs, and promote DCs maturation to induce neoantigen-specific T cells. Moreover, in mouse orthotopic liver cancer and humanized mouse tumor models, ePAC combined with anti-TIM-3 exhibited remarkable antitumor efficacy. Overall, these results support that ePAC could be safely utilized as cancer vaccines for antitumor therapy, showing significant potential for clinical translation.
-
- Cancer Biology
- Structural Biology and Molecular Biophysics
MET is a receptor tyrosine kinase (RTK) responsible for initiating signaling pathways involved in development and wound repair. MET activation relies on ligand binding to the extracellular receptor, which prompts dimerization, intracellular phosphorylation, and recruitment of associated signaling proteins. Mutations, which are predominantly observed clinically in the intracellular juxtamembrane and kinase domains, can disrupt typical MET regulatory mechanisms. Understanding how juxtamembrane variants, such as exon 14 skipping (METΔEx14), and rare kinase domain mutations can increase signaling, often leading to cancer, remains a challenge. Here, we perform a parallel deep mutational scan (DMS) of the MET intracellular kinase domain in two fusion protein backgrounds: wild-type and METΔEx14. Our comparative approach has revealed a critical hydrophobic interaction between a juxtamembrane segment and the kinase ⍺C-helix, pointing to potential differences in regulatory mechanisms between MET and other RTKs. Additionally, we have uncovered a β5 motif that acts as a structural pivot for the kinase domain in MET and other TAM family of kinases. We also describe a number of previously unknown activating mutations, aiding the effort to annotate driver, passenger, and drug resistance mutations in the MET kinase domain.
